According to a new report, Asia Pacific DNA Diagnostics Market, published by KBV Research, the Asia Pacific DNA Diagnostics Market is expected to grow at a CAGR of 14.6% during 2016 -2022.
The China market dominated the Asia Pacific DNA Diagnostics Market in 2015, and would reach a market size of $1,478.2 million by 2022, growing at a CAGR of 10.8% during the forecast period. However, India market is expected to grow at CAGR of 16.5% during 2016-2022.
The Instruments market contributed the larger revenue share to the Asia Pacific DNA Diagnostics Market in 2015, and is expected to grow at a CAGR of 15.1% during the forecast period.
The report highlights the adoption of DNA Diagnostics in Asia Pacific.Based on the Product Types, the Asia Pacific DNA Diagnostics Market is segmented into Instruments, Reagents and Service & software segment. Based on the Application, the market is bifurcated into Oncology, Infectious disease testing, Myogenic disorder diagnosis, Clinical confirmation diagnostics, Prenatal diagnosis, Pre-implantation diagnostics andother segments. Based on the Technology, the market is bifurcated into PCR, Microarrays, In situ hybridization, Sequencing Technology, Mass Spectrometry andother segments. Further, the market is segmented into POC (Point-of-Care), Central Laboratories and Self-Testing segments based on the End Users. The countries included in the report are China, Japan, India, South Korea, Singapore, Malaysia and Rest of Asia Pacific.
Key Players profiled in the report includes Sysmex Corporation, Bayer Corporation, Roche Diagnostics, Abbott Laboratories, Cepheid Inc, Hologic Corporation, Illumina, Novartis International Ag, Thermo Fisher Scientific Inc. and Bio-Rad Laboratories.
Full report: https://www.kbvresearch.com/asia-pacific-dna-diagnostics-market/
The market is segmented based on Product Types, Application, Technology, End User and Country.
Related Reports-
Unique Offerings 
